CHIRON |
Science For Life™
TRAFFIC:  Study Design
•Phase II, double-blind, placebo-controlled, regimen finding study
•Dose: 30 mg/kg (MTD from CAD Phase I)
•Route: Bilateral intra-arterial, days 1 and 30
•Groups: Placebo, SINGLE, DOUBLE
•Primary Endpoint:  change in PWT at Day 90
•Secondary Endpoints: 
–PWT at 180 days
–QOL at 90 and 180 days
–COT and ABI at 90 and 180 days
–